Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs Workday Inc (WDAY) Price & Performance

Abeona Therapeutics IncTrade
Workday IncTrade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs Workday Inc — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Workday Inc trades at $174 (market cap $44.77B). The key difference: Workday Inc is far larger — about 106.3× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Workday Inc nearer its low. Which is the better fit depends on your goals.

ABEOWDAY
Market Cap
$421.19M$44.77B
Sector
HealthTechnology
52-Week High
$7.45$247.69
52-Week Low
$4.17$112.55
Enterprise Value
$276.10M$44.22B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.

The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.

Workday Inc

Workday (WDAY) trades at $174.5, down 5.26% over 24 hours, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong revenue growth, reaching $8.45B in 2025, with consistent earnings beats and a high gross margin of 75.77%. Recent news highlights product launches like Workday Adaptive Planning's FedRAMP authorization and an AI-native learning platform, reinforcing its enterprise software leadership.

Outlook remains positive with robust fundamentals and analyst support, though elevated valuation ratios like a P/E of 56.47 pose risks. Key opportunities include AI-driven growth in HR and finance software, while risks involve competitive pressures and market volatility. The consensus price target of $153.33 suggests caution near current levels, but long-term growth prospects are solid.

Returns comparison

Trailing returns across standard periods

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About Workday Inc

Workday is a software company that offers human capital management, or HCM, financial management, and business planning solutions. Known for being a cloud-only software provider, Workday is headquartered in Pleasanton, California. Founded in 2005, Workday now employs over 12,000 employees.

Read more on WDAY